Compare Marqeta Inc (MQ) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Smith & Nephew plc — how do they compare? Marqeta Inc trades at $18.11 (market cap $1.82B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 6.1× Marqeta Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Smith & Nephew plc for 121 Days on average.
| MQ | SNN | |
|---|---|---|
Market Cap | $1.82B | $11.10B |
Volume | 1,126,466 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $20.32 | $37.17 |
52-Week Low | $15.04 | $26.42 |
Typical Hold Time | 44 Days | 121 Days |
Enterprise Value | $1.13B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.11, up 6.15% with a bullish technical signal. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, while revenue grew 23% year-over-year to $625M in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. However, valuation remains elevated with a P/E of 193.83 and negative EBITDA of -$19.27M despite improving cash flow trends.
Outlook remains mixed with analyst consensus at Hold (59% of ratings) and a $11.38 price target suggesting 37% downside. Key risks include contract renewals in Q3 2026 potentially slowing growth, while institutional sentiment is cautious despite technical strength. The stock's premium valuation requires sustained execution to justify current levels.
Smith+Nephew (SNN) trades at $27.24, near its 52-week low of $27.05, with a bearish technical signal despite recent earnings beats. Revenue grew to $6.16B in 2025, with net income margin improving to 10.08%, but the stock faces headwinds from analyst downgrades and CFO departure news. Product launches like the EVOS PELVIC System highlight innovation, yet investor sentiment remains cautious.
The outlook is mixed: strong fundamentals and undervaluation (P/E 18.34) offer upside, but technical weakness and competitive risks temper near-term gains. Key risks include execution challenges and market volatility, while institutional interest (e.g., BlackRock's $505M stake) provides support. Investors should weigh solid profitability against sentiment-driven price pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
